EP3383390A4 - Composés de pipéridinyle pour récepteur de nociceptine - Google Patents

Composés de pipéridinyle pour récepteur de nociceptine Download PDF

Info

Publication number
EP3383390A4
EP3383390A4 EP16871683.5A EP16871683A EP3383390A4 EP 3383390 A4 EP3383390 A4 EP 3383390A4 EP 16871683 A EP16871683 A EP 16871683A EP 3383390 A4 EP3383390 A4 EP 3383390A4
Authority
EP
European Patent Office
Prior art keywords
piperidinyl
nociceptin receptor
receptor compounds
compounds
nociceptin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP16871683.5A
Other languages
German (de)
English (en)
Other versions
EP3383390A1 (fr
Inventor
Nurulain T. Zaveri
Michael Meyer
V. Blair JOURNIGAN
Dennis Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astraea Therapeutics LLC
Original Assignee
Astraea Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58798102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3383390(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astraea Therapeutics LLC filed Critical Astraea Therapeutics LLC
Publication of EP3383390A1 publication Critical patent/EP3383390A1/fr
Publication of EP3383390A4 publication Critical patent/EP3383390A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
EP16871683.5A 2015-12-02 2016-12-02 Composés de pipéridinyle pour récepteur de nociceptine Pending EP3383390A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562261871P 2015-12-02 2015-12-02
PCT/US2016/064854 WO2017096323A1 (fr) 2015-12-02 2016-12-02 Composés de pipéridinyle pour récepteur de nociceptine

Publications (2)

Publication Number Publication Date
EP3383390A1 EP3383390A1 (fr) 2018-10-10
EP3383390A4 true EP3383390A4 (fr) 2019-11-20

Family

ID=58798102

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16871683.5A Pending EP3383390A4 (fr) 2015-12-02 2016-12-02 Composés de pipéridinyle pour récepteur de nociceptine

Country Status (8)

Country Link
EP (1) EP3383390A4 (fr)
JP (3) JP7011596B2 (fr)
KR (1) KR20180094940A (fr)
CN (1) CN108883103A (fr)
AU (2) AU2016365400C1 (fr)
CA (1) CA3006966A1 (fr)
IL (1) IL259726B (fr)
WO (1) WO2017096323A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN117642402A (zh) * 2021-07-14 2024-03-01 宜昌人福药业有限责任公司 一种螺哌啶环衍生物及其药物组合物、制备方法和用途
EP4345096A1 (fr) * 2021-07-14 2024-04-03 Yichang Humanwell Pharmaceutical Co., Ltd. Dérivé de pipéridine, et composition pharmaceutique de celui-ci, procédé de préparation correspondant et utilisation associée

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254895A1 (fr) * 2000-01-20 2002-11-06 Eisai Co., Ltd. Composes azotes cycliques et compositions pharmaceutiques les contenant
EP1308439A1 (fr) * 2000-08-10 2003-05-07 Welfide Corporation Derives de proline et leur utilisation comme medicaments
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005060947A2 (fr) * 2003-12-19 2005-07-07 Sri International Ligands agonistes et antagonistes du recepteur de la nociceptine
WO2008060621A2 (fr) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
EP2141163A1 (fr) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Thiazolidinone substituée, sa fabrication et son utilisation en tant que médicament
WO2011029915A1 (fr) * 2009-09-10 2011-03-17 Novartis Ag Dérivés éthers d'hétéroaryles bicycliques
WO2011101409A1 (fr) * 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
WO2014157687A1 (fr) * 2013-03-29 2014-10-02 大鵬薬品工業株式会社 Dérivé 1,2,4-triazine-6-carboxamide ayant un groupe acétamide
WO2014174021A1 (fr) * 2013-04-24 2014-10-30 Janssen Pharmaceutica Nv Dérivés de 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs de nik dans le traitement du cancer
WO2014184069A1 (fr) * 2013-05-14 2014-11-20 Nerviano Medical Sciences S.R.L. Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases
WO2015044269A1 (fr) * 2013-09-26 2015-04-02 Janssen Pharmaceutica Nv Nouveaux dérivés de 3-(1bh-pyrazol-4-yl)-1h-pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs de la nik
EP2878601A1 (fr) * 2012-07-27 2015-06-03 Riken Agent destiné à traiter ou à supprimer une récidive de leucémie myélogène aiguë
WO2016062791A1 (fr) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv Nouveaux dérivés de pyrazole utilisés comme inhibiteurs de nik
WO2016062789A1 (fr) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv Nouveaux dérivés de thiénopyrimidine utiles en tant qu'inhibiteurs de nik

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (fr) * 1993-12-23 2010-01-27 Eli Lilly And Company Inhibiteurs de la protéine-kinase c
CA2226058C (fr) * 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag Derives de substitution en 8 de 1,3,8-triazaspiro[4.5]decan-4-one
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
JP3966693B2 (ja) 2000-01-20 2007-08-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 含窒素環化合物およびそれらを含んでなる医薬組成物
AU2000240570A1 (en) 2000-03-29 2001-10-08 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
WO2003095427A1 (fr) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Compose a noyau spiranique
EA009369B1 (ru) * 2002-09-09 2007-12-28 Янссен Фармацевтика, Н.В. Производные гидроксизамещенного 1,3,8-триазинспиро[4,5]декан-4-она, полезные для лечения расстройств, опосредованных orl-рецептором
WO2005092895A2 (fr) 2004-03-29 2005-10-06 Pfizer Japan Inc. Composes acide propanoique beta piperidino methyle alpha aryle ou heteroaryle utilises comme antagonistes du recepteur orl1
US7655670B2 (en) 2005-06-02 2010-02-02 Janssen Pharmaceutica N.V. 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
JP5490677B2 (ja) 2007-04-09 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 不安及び鬱病の処置のためのｏｒｌ−１受容体リガンドとしての１，３，８−三置換−１，３，８−トリアザ−スピロ［４．５］デカン−４−オン誘導体
US9963458B2 (en) * 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1254895A1 (fr) * 2000-01-20 2002-11-06 Eisai Co., Ltd. Composes azotes cycliques et compositions pharmaceutiques les contenant
EP1308439A1 (fr) * 2000-08-10 2003-05-07 Welfide Corporation Derives de proline et leur utilisation comme medicaments
WO2004056830A1 (fr) * 2002-12-19 2004-07-08 Pfizer Products Inc. Derives de pyrrolopyrimidine
WO2005060947A2 (fr) * 2003-12-19 2005-07-07 Sri International Ligands agonistes et antagonistes du recepteur de la nociceptine
WO2008060621A2 (fr) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines utilisés en tant qu'antagonistes du récepteur de la chimiokine
EP2141163A1 (fr) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Thiazolidinone substituée, sa fabrication et son utilisation en tant que médicament
WO2011029915A1 (fr) * 2009-09-10 2011-03-17 Novartis Ag Dérivés éthers d'hétéroaryles bicycliques
WO2011101409A1 (fr) * 2010-02-19 2011-08-25 Novartis Ag Composés de la pyrrolopyrimidine utilisés en tant qu'inhibiteurs des cdk4/6
EP2878601A1 (fr) * 2012-07-27 2015-06-03 Riken Agent destiné à traiter ou à supprimer une récidive de leucémie myélogène aiguë
WO2014157687A1 (fr) * 2013-03-29 2014-10-02 大鵬薬品工業株式会社 Dérivé 1,2,4-triazine-6-carboxamide ayant un groupe acétamide
WO2014174021A1 (fr) * 2013-04-24 2014-10-30 Janssen Pharmaceutica Nv Dérivés de 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1h-pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs de nik dans le traitement du cancer
WO2014184069A1 (fr) * 2013-05-14 2014-11-20 Nerviano Medical Sciences S.R.L. Dérivés de 6-amino-7-désaza-purine, procédé pour les préparer et leur utilisation comme inhibiteurs de kinases
WO2015044269A1 (fr) * 2013-09-26 2015-04-02 Janssen Pharmaceutica Nv Nouveaux dérivés de 3-(1bh-pyrazol-4-yl)-1h-pyrrolo[2,3-c]pyridine en tant qu'inhibiteurs de la nik
WO2016062791A1 (fr) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv Nouveaux dérivés de pyrazole utilisés comme inhibiteurs de nik
WO2016062789A1 (fr) * 2014-10-23 2016-04-28 Janssen Pharmaceutica Nv Nouveaux dérivés de thiénopyrimidine utiles en tant qu'inhibiteurs de nik

Also Published As

Publication number Publication date
KR20180094940A (ko) 2018-08-24
AU2016365400A1 (en) 2018-06-21
IL259726A (en) 2018-07-31
JP2022036285A (ja) 2022-03-04
EP3383390A1 (fr) 2018-10-10
JP7472175B2 (ja) 2024-04-22
IL259726B (en) 2021-10-31
JP7011596B2 (ja) 2022-02-10
CN108883103A (zh) 2018-11-23
AU2016365400C1 (en) 2022-11-10
AU2016365400B2 (en) 2022-04-07
JP2018536716A (ja) 2018-12-13
AU2022202862B2 (en) 2024-03-28
JP2024003167A (ja) 2024-01-11
CA3006966A1 (fr) 2017-06-08
AU2022202862A1 (en) 2022-05-19
WO2017096323A1 (fr) 2017-06-08

Similar Documents

Publication Publication Date Title
GB201514875D0 (en) Receptor
EP3523306A4 (fr) Composés spirocycliques
EP3325449A4 (fr) Composés
EP3248300A4 (fr) Rétroaction d'informations d'état de canal (csi) améliorée pour des opérations entrées multiples, sorties multiples (mimo) globales (fd) (fd-mimo)
HK1252163A1 (zh) 受體
EP3224246A4 (fr) Composés de 4-oxoquinoléine
EP3099695A4 (fr) Composés
EP3099694A4 (fr) Composés
EP3172208A4 (fr) Composés
IL250888A0 (en) Transmuted piperidine compounds
EP3319444A4 (fr) Modulateurs du récepteur opioïde de type mu
EP3095185A4 (fr) Élément de maçonnerie à revêtement photovoltaïque
EP3227309A4 (fr) Difucosyllactose cristallin
HK1256671A1 (zh) 螺環化合物
ZA201606141B (en) Piperidine derivatives as orexin receptor antagonist
EP3110792A4 (fr) Composés d'aminocarbonylcarbamate
EP3202516A4 (fr) Structure de mandrin
EP3129017A4 (fr) Promédicament à base de platine (iv) ciblant les mitochondries
EP3152190A4 (fr) Composés bi-polycycliques de 18 à 20 éléments
EP3310352A4 (fr) Composés cristallins
EP3149010A4 (fr) Composés monoaminosilane
EP3097912A4 (fr) Antagoniste de la mégaline
IL259726B (en) Nociceptin piperidinyl receptor compounds
EP3350167A4 (fr) Antagonistes du récepteur des androgènes
EP3255044A4 (fr) Composés diaza-benzofluoranthrène

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180531

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/04 20060101AFI20190709BHEP

Ipc: A61K 31/44 20060101ALI20190709BHEP

Ipc: C07D 471/10 20060101ALI20190709BHEP

Ipc: C07D 405/14 20060101ALI20190709BHEP

Ipc: C07D 401/14 20060101ALI20190709BHEP

Ipc: A61P 29/00 20060101ALI20190709BHEP

Ipc: C07D 471/04 20060101ALI20190709BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20191023

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/14 20060101ALI20191017BHEP

Ipc: C07D 471/04 20060101ALI20191017BHEP

Ipc: C07D 471/10 20060101ALI20191017BHEP

Ipc: A61P 29/00 20060101ALI20191017BHEP

Ipc: A61K 31/44 20060101ALI20191017BHEP

Ipc: C07D 401/14 20060101ALI20191017BHEP

Ipc: C07D 401/04 20060101AFI20191017BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261973

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220510